Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Conference News ACC 2023

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

Shelley Wood

March 10, 2023

News Conference News ACC 2023

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

Michael O'Riordan

March 07, 2023

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

Shelley Wood

February 27, 2023

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

L.A. McKeown

May 15, 2021

Presentation ACC 2019

Initiation of Angiotensin-Neprilysin Inhibition after Acute Decompensated Heart Failure: Results of the Open-Label Extension of the PIONEER-HF Trial

Presenter: Adam D. DeVore

March 17, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Conference News ACC 2018

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Michael O'Riordan

March 01, 2018

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Shelley Wood

March 23, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

L.A. McKeown

March 09, 2017

News Conference News ACC 2016

CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results

Shelley Wood

April 08, 2016

News Conference News ACC 2016

‘Enhanced’ Multicellular Stem Cell Therapy Improves Clinical Outcomes in Heart Failure: ixCELL-DCM Study

Michael O'Riordan

April 04, 2016

Presentation ACC 2014

Stem Cells: Regenerate Failing Hearts - Results from the MSC-HF Trial

Presenter: Anders Bruun Mathiasen

March 31, 2014

News Conference News ACC 2014

Intramyocardial Injection of Stem Cells Shows Promise for Severe Ischemic Heart Failure

Yael L. Maxwell

March 31, 2014

Presentation ACC 2012

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Ischemic Heart Failure: The FOCUS-CCTRN Trial

Presenter: Emerson C. Perin

March 25, 2012

Advertisement

What’s Going to Be Hot at ACC 2025?

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

What’s Going to Be Hot at ACC/WCC 2023?

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

What’s Going to Be Hot at ACC 2022, In Person or Virtual

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

Initiation of Angiotensin-Neprilysin Inhibition after Acute Decompensated Heart Failure: Results of the Open-Label Extension of the PIONEER-HF Trial

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results

‘Enhanced’ Multicellular Stem Cell Therapy Improves Clinical Outcomes in Heart Failure: ixCELL-DCM Study

Stem Cells: Regenerate Failing Hearts - Results from the MSC-HF Trial

Intramyocardial Injection of Stem Cells Shows Promise for Severe Ischemic Heart Failure

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Ischemic Heart Failure: The FOCUS-CCTRN Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content